CTRI/2018/02/011868
Completed
未知
Evaluation of appropriateness and pharmacoeconomics of surgical antimicrobial prophylaxis in open reduction internal fixation surgery based on NCDC guidelines
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Patients with closed fracture posted for open reduction internal fixation surgery
- Sponsor
- KIMS hospital
- Enrollment
- 412
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •closed fracture cases of more than 18 years of age, irrespective of gender, who were posted for ORIF surgery
Exclusion Criteria
- •Cases unwilling to give informed consent, open fracture, cases posted for delayed primary or secondary closure procedures, cases already receiving antimicrobials
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
To evaluate the efficacy, safety and pharmacoeconomics of Shiwei Longdanhua capsule in the treatment of acute tracheo-bronchitis (phlegm-heat obstructing lung syndrome)Acute tracheobronchitisITMCTR2200006863The Second Affiliated Hospital of Tianjin University of Chinese Medicine
Not yet recruiting
Not Applicable
pharmacoeconomic evaluation of antidiabetic drugsHealth Condition 1: E116- Type 2 diabetes mellitus with other specified complicationsHealth Condition 2: E116- Type 2 diabetes mellitus with other specified complicationsCTRI/2023/07/055043Deeksha M
Active, not recruiting
Phase 1
Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inherited VWD and frequent bleedings - PRO.WIpatients with severe inherited VWD unresponsive to DDAVP and with frequent bleedingsMedDRA version: 8.1Level: PTClassification code 10047715Term: Von Willebrand's diseaseEUCTR2006-001383-23-ITFONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI24
Active, not recruiting
Phase 1
Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inherited VWD and frequent bleedings.Severe, inherited von Willebrand disease (VWD) and frequent bleedingsMedDRA version: 14.1 Level: PT Classification code 10047715 Term: Von Willebrand's disease System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2006-001383-23-GBProf Flora Peyvandi, MD24
Active, not recruiting
Phase 1
Efficacy, safety and pharmaco-economic assessment ofsecondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inherited VWDand frequent bleedingsPatients with severe, inherited Von Willebrand’s disease and frequent bleedingsMedDRA version: 16.0Level: PTClassification code 10047715Term: Von Willebrand's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2006-001383-23-DEFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico24